Non-BRCA1/2 hereditary breast cancer linked to new cancers

The risk for a new cancer in the unaffected breast substantially increases in women diagnosed with unilateral, hereditary (non-BRCA1/2) breast cancer, according to a new study by researchers working at Karolinska Institutet in Stockholm, Sweden.

The study is the first in its kind and is published in the March 15, 2006 issue of CANCER.

Women with hereditary (non-BRCA1/2) breast cancer are estimated to be at up to six times greater risk of developing a second primary malignancy in the other breast, also known as contralateral breast cancer (CBC), than the general population is of developing primary breast cancer. Young age at first diagnosis, family history of breast cancer, and confirmed BRCA1 or BRCA2 gene mutations are the primary risk factors for CBC. However, the contribution of non-BRCA1/2 hereditary cancers to the risk of CBC is poorly understood.

A group of researchers at Karolinska Institutet and Umeå Universitet in Sweden reviewed data from 120 families and 204 women with unilateral breast cancer and a family history of breast cancer but no BRCA mutations to better characterize the CBC risk for these women.

They found that the long term CBC risk was significantly higher in women with hereditary breast cancer compared to the risk of developing a primary breast cancer in the general population. The overall probability for these women was 5.5 percent at 5 years and up to 27.3 percent at 20 years compared to only 1.9 percent at 5 years and 4.9 percent at 20 years for the general population. Further analysis by age group showed clearly that the 15 year probability of developing a CBC was significantly elevated for women with a diagnose before age 50 compared to women at an older age (40 percent and 10 percent, respectively).

Women who received adjuvant hormonal therapy had significantly lowered risk for a CBC compared to those who did not take it. Adjuvant chemotherapy had no apparent effect on risk.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Adding high-dose IV vitamin C to chemotherapy can boost survival for pancreatic cancer patients